• The FDA is reviewing ImmunityBio’s Anktiva in combination with BCG for papillary-only bladder cancer, with a decision date set for January 6, 2027, while Sheets Smith Wealth Management recently trimmed its position and retail investor discussion volumes rose very sharply on speculation about regulatory and commercial outcomes.
• This mix of an upcoming regulatory decision and a spike in retail interest highlights how expectations around Anktiva’s future use are shaping sentiment toward ImmunityBio’s broader immunotherapy platform.
• With the FDA decision on Anktiva plus BCG now a focal point, we’ll examine how this regulatory milestone could influence ImmunityBio’s investment narrative.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

ImmunityBio Investment Narrative Recap

To own ImmunityBio, you need to believe ANKTIVA can anchor a broader immunotherapy franchise beyond its current bladder cancer foothold. The FDA’s Anktiva plus BCG review for papillary-only disease is the key near term catalyst, and the January 6, 2027 action date keeps the regulatory timeline in clear focus. The latest FDA update and spike in retail chatter do not change the fundamental risk that ImmunityBio is still heavily dependent on ANKTIVA’s regulatory and commercial trajectory.

The May 20 FDA acceptance of the supplemental Biologics License Application for ANKTIVA plus BCG in papillary-only NMIBC is the announcement most tied to this news. It formalized the PDUFA date now in view and framed how the agency will assess extrapolation from CIS data. In the context of upcoming catalysts, this filing crystallizes the next major U.S. inflection point for ANKTIVA and gives investors a concrete timeline to track against broader pipeline and commercialization goals.

Yet even if Anktiva plus BCG progresses, investors should be aware that concentrated reliance on a single drug and indication means...

ImmunityBio's narrative projects $1.6 billion revenue and $673.2 million earnings by 2029. This requires 125.9% yearly revenue growth and a $1.53 billion earnings increase from -$854.5 million today.

Uncover how ImmunityBio's forecasts yield a $13.00 fair value, a 65% upside to its current price.

Exploring Other Perspectives

Before this FDA update, the most optimistic analysts were modeling revenue reaching about US$1.6 billion and earnings of roughly US$671.9 million, which is far more optimistic than the consensus view. If you are weighing those projections against today’s Anktiva plus BCG review and retail speculation, it is worth asking how such bullish expectations might shift if regulatory timelines or real world adoption look different from what those analysts were assuming.

Explore 10 other fair value estimates on ImmunityBio - why the stock might be worth over 5x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your ImmunityBio research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 44 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.